Bipolar Disorder and Parkinson's Disease: A (123)I-Ioflupane Dopamine Transporter SPECT Study(245 views) Erro R, Landolfi A, D , #xagostino G, Pace L, Picillo M, Scarano M, Cuocolo A, Pappata S, Vitale C, Pellecchia MT, Monteleone P, Barone P
Front Neurol (ISSN: 1664-2295linking, 1664-2295print), 2021 Apr 13; 12: 652375-652375.
Keywords: Datscan, Antipsychotics (also Called Neuroleptics), Degeneration, Dopamine Transporter, Lithium,
Affiliations: *** IBB - CNR ***
Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy., Department of Diagnostic Imaging and Radiotherapy, Azienda Ospedaliera Universitaria (AOU) San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy., Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy., Institute of Biostructure and Bioimaging, National Council of Research, Naples, Italy., Department of Motor Sciences and Wellness, University Parthenope, Naples, Italy.,
References: Not available.
Bipolar Disorder and Parkinson's Disease: A (123)I-Ioflupane Dopamine Transporter SPECT Study
Objectives: Bipolar disorder (BD) has been suggested to be a risk factor for the development of Parkinson's disease (PD). Standard treatment of BD includes drugs that are known to induce drug-induced parkinsonism (DIP). Clinical differentiation between PD and DIP is crucial and might be aided by functional neuroimaging of the dopaminergic nigrostriatal pathway. Methods: Twenty consecutive BD patients with parkinsonism were clinically assessed and underwent (123)I-ioflupane dopamine transporter single-photon emission computer tomography (SPECT). Imaging data of BD patients with pathological scans were further compared to a population of 40 de novo PD patients. Results: Four BD patients had abnormal scans, but their clinical features and cumulative exposure to both antipsychotic drugs and lithium were similar to those of BD patients with normal dopamine transporter imaging. BD patients with pathological scans had putaminal binding ratio and putamen-to-caudate ratios higher than those of PD patients despite a similar motor symptom burden. Conclusions: Up to 20% of BD patients with parkinsonism might have an underlying dopaminergic deficit, which would not be due to cumulative exposure to offending drugs and is ostensibly higher than expected in the general population. This supports the evidence that BD represents a risk factor for subsequent development of neurodegenerative parkinsonism, the nature of which needs to be elucidated.
Bipolar Disorder and Parkinson's Disease: A (123)I-Ioflupane Dopamine Transporter SPECT Study
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(884 views) Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 ViewExport to BibTeXExport to EndNote